Skip to main content
ANRO
NYSE Life Sciences

Alto Neuroscience Q3 Loss Widens to $25.1M; $319.8M Cash Funds Operations Through 2030

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$28.61
Mkt Cap
$1.123B
52W Low
$10.8
52W High
$37.48
52W Position info
165% above low
Off High info
24% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ANRO has more than doubled off its 52-week low of $10.8.

Summary

Alto Neuroscience reported a wider Q3 2026 net loss of $25.1 million, but $319.8 million in cash funds operations through 2030, while ALTO-207 PACE-1 topline remains on track for 2H 2027.


Key Events · Earnings and Guidance · ANRO

  • Q3 Loss Widens on PACE Spending

    Net loss was $25.1 million versus $14.2 million a year earlier. R&D rose to $18.2 million from $10.5 million and G&A to $9.1 million from $4.4 million, driven by the ALTO-207 PACE program and headcount.

  • Cash Runway Extended Through 2030

    Cash, cash equivalents and restricted cash totaled $319.8 million at September 30, 2026, up from $177.0 million at December 31, 2025, after the July 2026 offering of 3,776,436 shares at $26.48 for $100.0 million gross (~$94.6 million net).

  • ALTO-207 Timelines Pushed to 2027

    PACE-1 Phase 2b topline is expected in 2H 2027; PACE-2 Phase 3 initiation in early 2027 pending FDA alignment; PACE-3 monotherapy initiation in 2H 2027. FDA interaction outcome and Phase 1 data are expected late 2026 or early 2027.

  • ALTO-300 and ALTO-100 Readouts Ahead

    Phase 2b topline data are expected in 1H 2027 for ALTO-300 in MDD and mid-2027 for ALTO-100 in bipolar depression, with enrollment ongoing.


Analysis · ANRO · Life Sciences

The balance sheet is the story here: $319.8 million in cash after the July $100 million raise, enough to fund operations through 2030. That removes near-term financing risk and lets management expand ALTO-207 Phase 3 plans to both monotherapy and adjunctive trials. The quarter's loss widened to $25.1 million from $14.2 million a year ago as spending on the ALTO-207 PACE program ramped. The trade-off is time — PACE-1 topline now lands in 2H 2027, with the FDA interaction and Phase 1 data not until late 2026 or early 2027, so the next hard catalyst is still months away.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANRO was trading at $28.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $10.80 to $37.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANRO - Latest Insights

ANRO
Aug 12, 2026, 4:27 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.50
Real-time Price: $31.15 info
Change: +$2.65 (+9%) info
Market Cap: $1.222B info
ANRO
Aug 12, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.18
Real-time Price: $31.15 info
Change: +$1.97 (+7%) info
Market Cap: $1.222B info
ANRO
Jul 14, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $31.15 info
Change: +$2.65 (+9%) info
Market Cap: $1.222B info
ANRO
Jul 14, 2026, 6:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $31.15 info
Change: +$2.65 (+9%) info
Market Cap: $1.222B info
ANRO
Jul 14, 2026, 6:03 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $31.15 info
Change: +$2.65 (+9%) info
Market Cap: $1.222B info